Quantified Evaluation of Whole Face 8-points Supra-periosteum High Molecular Weight Hyaluronic Acid Injection in Asian

Exclusion Criteria

• •1. Subjects with a history of anaphylaxis, allergy hyaluronic acid products, or any component of devices.
• •2. Subjects with autoimmune diseases/ received immune system and Subjects with diabetes mellitus.
• •3. Subjects with a history of a hypertrophic scar.
• •4. Pregnant or breastfeeding women.
• •5. Subjects with epilepsy or underlying porphyria.
• •6. When there is inactive disease (such as inflammation, infection or tumours) in or near the intended treatment site.
• •7. Treatment procedure (e.g., bioresorbable fillers, laser/light therapies, botulinum toxin A injections, face lift, facial peels, excisional facial surgery, dermal photorejuvenation clinically significant oral or maxillofacial surgery, etc.) that may interfere with the treatment area or evaluation within 6 months prior to screening as determined by the Principal Investigator.
• •8. The subject who received soft tissue augmentation as following at the investigational medical device injection site within 6 months prior to screening as determined by the Principal Investigator.
• •9. The subject who received soft tissue augmentation near the injection site with any of the following at any time.
• •10. Subjects with a scar or skin lesion at the investigational medical device injection site that may interfere with the judgment of the treatment effect.
• •11. Subjects who participated in another clinical trial within 60 days prior to screening or plan to participate in another investigation during the course of this study.
• •12. Subjects who plan to receive other wrinkle improvement treatment in the face during this trial.
• •13. Subjects who are otherwise determined by the investigator as ineligible for this study.